Linezolid is an oxazolidinone antibiotic, mainly used to treat infections caused by gram-positive (G+) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) caused by methicillin-resistant Staphylococcus aureus (MRSA), community-acquired pneumonia (CAP), complex skin or skin and soft tissue infections (SSTI), and vancomycin-resistant enterococcus (VRE) infections. Linezolid’s product ZYVOX was developed by Pfizer Pharmaceuticals. It was approved to enter the Chinese market in 2006. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, by 2020, there are several manufacturers besides Pfizer in the Linezolid market in China.
According to CRI’s market research, the sales value of Linezolid in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Linezolid in the Chinese market fell to CNY695 million in 2020, a year-on-year decrease of 14.89%. However, the CAGR of Linezolid sales value in the Chinese market from 2016 to 2020 is still 14.45%.
CRI expects that with the relief of COVID-19, the sales value of Linezolid in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Linezolid has high antibacterial activity against Staphylococcus, Streptococcus pneumoniae, and Enterococcus bacteria, and has no cross-resistance with other antibacterial drugs. It is currently the first choice for the treatment of severe infections such as septic shock. These advantages make sales value and sales volume have room to rise.
- -The impact of COVID-19 on China’s Linezolid market
- – Sales value of China’s Linezolid 2016-2020
- – Competitive landscape of China’s Linezolid market
- – Prices of Linezolid in China
- – Prices of Linezolid in China by regions and manufacturers
- – Analysis on factors affecting the development of China’s Linezolid market
- – Prospect of China’s Linezolid market from 2021 to 2025